Columbia University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Columbia University sits in the top decile of US sponsors by registered trial count (#34 of 15,742 sponsors by registered trial count).

958 total trials 171 currently recruiting 597 completed early-phase tilt top decile by trial count

Columbia University: 958 sponsored US clinical trials, 171 recruiting.

Columbia University sponsors 958 registered US clinical trials on ClinicalTrials.gov, 171 of them currently recruiting, and 597 completed. 88 of these trials are in Phase 3-4 (later-stage) and 191 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 9 trials.

Top-decile sponsor footprint

Columbia University ranks in the top decile of sponsors by registered trial count (#34 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 42/100

597 of 736 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

958 total, page 17 of 20

COMPLETED Phase 1

Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients

NCT00997022

COMPLETED NA

Undiagnosed Diabetes in a Dental Setting

NCT01711385

COMPLETED

Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma

NCT01219829

COMPLETED NA

The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial

NCT00835289

TERMINATED

Validation of a Mouse Model of Pancreatic Carcinogenesis

NCT01103128

COMPLETED Phase 4

Effect of Oral Choline Supplementation on Postoperative Pain

NCT00720343

COMPLETED Phase 2

Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2

NCT01976936

COMPLETED

Cognitive Dysfunction in Hypertensive Patients Having Spine Surgery

NCT01140854

COMPLETED NA

Fresh Versus Old Red Blood Cells for Transfusion

NCT01319552

COMPLETED Phase 1

Intravesicular Abraxane for Treatment-Refractory Bladder Cancer

NCT00583349

TERMINATED Phase 2

P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.

NCT00524134

COMPLETED

Family and Personal History of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN)

NCT01104077

COMPLETED NA

Effect of Robot Rehabilitation Exercise Training on Motor Control After Stroke

NCT02331407

COMPLETED

Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis

NCT01279733

COMPLETED NA

Randomized Controlled Trial of Structured Contraceptive Counseling in Adult Women

NCT00746993

COMPLETED Phase 2

Feasibility of Delphi Screener for Cervical Cytology

NCT00702208

COMPLETED NA

Northern Manhattan Diabetes Community Outreach Project

NCT00787475

COMPLETED Phase 2

Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women

NCT00697463

COMPLETED

Intracardiac T-wave Alternans and Ischemia

NCT00669552

COMPLETED

T-wave Alternans and Intrathoracic Impedance Measurements

NCT00669682

COMPLETED Phase 4

Immediate Versus Delayed Insertion of the Copper Intrauterine Device (IUD) After Medication Abortion

NCT00737178

COMPLETED Phase 2

Metformin in Amnestic Mild Cognitive Impairment

NCT00620191

COMPLETED NA

Family Nurture Intervention (FNI) in Neonatal Intensive Care Unit (NICU)

NCT01439269

COMPLETED NA

Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®

NCT00710606

COMPLETED NA

Patient Outcomes in Simulation Education (POISE) Intravenous (IV) and Lumbar Puncture (LP) Multi-institution Protocol

NCT01548547

COMPLETED Phase 1

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

NCT00691210

COMPLETED Phase 1

Trial of Leptin Administration After Roux-en-Y Gastric Bypass

NCT00710814

TERMINATED

Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas

NCT00646308

TERMINATED NA

Comparision of Air Versus CO2 for Distention During Sigmoidoscopy

NCT00771290

TERMINATED

Impact of Tachycardia on Outcome After Subarachnoid Hemorrhage (SAH)

NCT01585311

COMPLETED Phase 2

Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations

NCT01983774

TERMINATED Phase 2

Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

NCT00859495

TERMINATED NA

Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)

NCT01363882

COMPLETED Phase 2

Effects of Tolcapone on Frontotemporal Dementia

NCT00604591

COMPLETED NA

Txt Now 2 Decrease Pregnancies L8r: A Study to Evaluate the Effect of Daily Text Message Reminders on Pill Continuation

NCT00677703

TERMINATED NA

Feasibility Study of Simvastatin in Hodgkin's Lymphoma Survivors

NCT00746603

TERMINATED Phase 1

Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

NCT00684957

COMPLETED NA

Training Cognitive Control Processes in Older Adults

NCT00586638

COMPLETED Phase 1

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

NCT00629343

TERMINATED Phase 1

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

NCT00801931

COMPLETED NA

Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation

NCT00563576

TERMINATED NA

Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis

NCT00537446

TERMINATED Phase 2

Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure

NCT00383630

TERMINATED Phase 1

Improving Medication Adherence in Post-ACS Patients

NCT00576160

COMPLETED NA

Post-treatment Care of Breast Cancer Survivors

NCT00821288

COMPLETED NA

Pre-Surgical Intervention for Targeted Therapies for Breast Cancer

NCT01004744

COMPLETED Phase 2

Effects of Physical Activity and Dietary Change in Minority Breast Cancer Survivors

NCT00811824

COMPLETED NA

The Impact of Pack Supply on Birth Control Pill Continuation

NCT00677742

COMPLETED NA

Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes

NCT00521222

COMPLETED NA

The Effects of Leucine on Body Weight

NCT00683826

← Previous Page 17 of 20 Next →

Phase Distribution

PhaseTrial count
Phase 1 86
Phase 2 105
Phase 3 23
Phase 4 65

What is open in the Columbia University pipeline

171 recruiting of 958 indexed (18% open); 597 completed (62%).

Phase mix: 88 late (III/IV) vs 191 early (I/II) (early-phase heavy).

Top condition: Obesity (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Columbia University: open-pipeline peers nationwide

Peers matched on 958 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Columbia University sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 5%10%15%20% Total trials Recruiting share Columbia UniversityUniversity of MinnesotaBrigham and Women's HospitalHoffmann-La RocheUniversity of California, Los AngelesKite, A Gilead CompanyMirum PharmaceuticalsWest Virginia UniversityHospital for Special Surgery, New York
Columbia University sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Columbia University sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 958 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Columbia University page

958 registered trials is a research-attention snapshot, not an endorsement of Columbia University or any single study.

  • 171 of Columbia University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Columbia University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Columbia University pipeline card: 958 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.